1616070-63-3

Upstream product

• 1616070-62-2 (R)-2-hydroxy-2-((R)-3-oxo-4-(1-((pivaloyloxy)methyl)-1H-pyrazol-3-yl)morpholin-2-yl)acetic acid 
• 32658-67-6 2-amino-5-iodoanthranilamide 
• 1616070-61-1 (3-((R)-2-((R)-2-(tert-butoxy)-1-hydroxy-2-oxoethyl)-3-oxomorpholin-4-yl)-1H-pyrazol-1-yl)methyl pivalate 
• 18997-19-8 Chloromethyl pivalate 
• 1616070-60-0 (3-iodo-1H-pyrazol-1-yl)methyl pivalate 

Relevant academic research and scientific papers

FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) (structurally represented) wherein R1, R2, R3 and R4 are independently H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl, and when R2, R3, and R4 are H, R1 is C1-6 alkyl; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

FACTOR IXa INHIBITORS

The present invention provides a compound of Formula (I) wherein A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more of said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.